SYRE Annual SG&A
$39.95 M
+$11.41 M+40.01%
31 December 2023
Summary:
As of January 21, 2025, SYRE annual selling, general & administrative expenses is $39.95 million, with the most recent change of +$11.41 million (+40.01%) on December 31, 2023. During the last 3 years, it has risen by +$18.10 million (+82.88%). SYRE annual SG&A is now at all-time high.SYRE Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE Quarterly SG&A
$10.65 M
-$863.00 K-7.50%
30 September 2024
Summary:
As of January 21, 2025, SYRE quarterly selling, general & administrative expenses is $10.65 million, with the most recent change of -$863.00 thousand (-7.50%) on September 30, 2024. Over the past year, it has increased by +$2.06 million (+24.04%). SYRE quarterly SG&A is now -24.33% below its all-time high of $14.07 million, reached on December 31, 2023.SYRE Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE TTM SG&A
-$3.34 B
-$214.90 M-6.89%
30 September 2024
Summary:
As of January 21, 2025, SYRE TTM selling, general & administrative expenses is -$3.34 billion, with the most recent change of -$214.90 million (-6.89%) on September 30, 2024. Over the past year, it has dropped by -$3.37 billion (-10877.40%). SYRE TTM SG&A is now -27056.70% below its all-time high of $49.08 million, reached on September 30, 2024.SYRE TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +40.0% | +24.0% | -10000.0% |
| 3 y3 years | +82.9% | +53.2% | -10000.0% |
| 5 y5 years | +216.2% | +53.2% | -10000.0% |
SYRE Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +46.2% | -24.3% | +109.7% | -165.1% | at low |
| 5 y | 5-year | at high | +153.9% | -24.3% | +145.2% | -409.4% | at low |
| alltime | all time | at high | +1826.0% | -24.3% | +3186.4% | <-9999.0% | at low |
Spyre Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.65 M(-7.5%) | $49.08 M(+4.4%) |
| June 2024 | - | $11.51 M(-10.4%) | $47.01 M(-1.2%) |
| Mar 2024 | - | $12.85 M(-8.7%) | $47.56 M(+19.1%) |
| Dec 2023 | $39.95 M(+40.0%) | $14.07 M(+63.9%) | $39.95 M(+29.1%) |
| Sept 2023 | - | $8.58 M(-28.8%) | $30.95 M(+5.6%) |
| June 2023 | - | $12.06 M(+130.7%) | $29.32 M(+17.6%) |
| Mar 2023 | - | $5.23 M(+2.9%) | $24.93 M(-12.6%) |
| Dec 2022 | $28.53 M(+4.4%) | - | - |
| Dec 2022 | - | $5.08 M(-26.9%) | $28.53 M(-7.2%) |
| Sept 2022 | - | $6.95 M(-9.4%) | $30.76 M(+0.4%) |
| June 2022 | - | $7.67 M(-13.0%) | $30.64 M(+2.9%) |
| Mar 2022 | - | $8.82 M(+20.8%) | $29.79 M(+9.0%) |
| Dec 2021 | $27.32 M(+25.1%) | $7.30 M(+6.8%) | $27.32 M(+1.1%) |
| Sept 2021 | - | $6.84 M(+0.2%) | $27.04 M(+4.5%) |
| June 2021 | - | $6.82 M(+7.4%) | $25.87 M(+9.0%) |
| Mar 2021 | - | $6.35 M(-9.5%) | $23.74 M(+8.7%) |
| Dec 2020 | $21.84 M(+38.8%) | $7.02 M(+23.8%) | $21.84 M(+14.0%) |
| Sept 2020 | - | $5.67 M(+20.9%) | $19.17 M(+7.7%) |
| June 2020 | - | $4.69 M(+5.2%) | $17.80 M(+5.2%) |
| Mar 2020 | - | $4.46 M(+2.7%) | $16.93 M(+7.6%) |
| Dec 2019 | $15.73 M | $4.34 M(+0.8%) | $15.73 M(+5.6%) |
| Sept 2019 | - | $4.31 M(+12.9%) | $14.90 M(+7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | $3.82 M(+16.8%) | $13.90 M(+6.8%) |
| Mar 2019 | - | $3.27 M(-6.8%) | $13.02 M(+3.0%) |
| Dec 2018 | $12.63 M(+25.5%) | $3.51 M(+5.8%) | $12.63 M(+10.4%) |
| Sept 2018 | - | $3.31 M(+13.3%) | $11.44 M(+2.6%) |
| June 2018 | - | $2.93 M(+1.4%) | $11.15 M(+5.3%) |
| Mar 2018 | - | $2.88 M(+24.5%) | $10.59 M(+5.2%) |
| Dec 2017 | $10.07 M(+20.0%) | $2.32 M(-23.3%) | $10.06 M(+2.7%) |
| Sept 2017 | - | $3.02 M(+27.7%) | $9.80 M(+10.8%) |
| June 2017 | - | $2.36 M(0.0%) | $8.84 M(-0.9%) |
| Mar 2017 | - | $2.36 M(+15.4%) | $8.93 M(+6.4%) |
| Dec 2016 | $8.39 M(+41.1%) | $2.05 M(-0.8%) | $8.39 M(+5.4%) |
| Sept 2016 | - | $2.06 M(-15.6%) | $7.96 M(+9.7%) |
| June 2016 | - | $2.45 M(+33.8%) | $7.25 M(+4.7%) |
| Mar 2016 | - | $1.83 M(+13.2%) | $6.93 M(+16.5%) |
| Dec 2015 | $5.95 M(+186.7%) | $1.62 M(+18.7%) | $5.95 M(+19.9%) |
| Sept 2015 | - | $1.36 M(-35.9%) | $4.96 M(+16.7%) |
| June 2015 | - | $2.12 M(+150.6%) | $4.25 M(+63.7%) |
| Mar 2015 | - | $847.00 K(+34.9%) | $2.60 M(+25.2%) |
| Dec 2014 | $2.07 M | $628.00 K(-3.8%) | $2.07 M(+43.4%) |
| Sept 2014 | - | $653.00 K(+39.2%) | $1.45 M(+82.3%) |
| June 2014 | - | $469.00 K(+44.8%) | $793.00 K(+144.8%) |
| Mar 2014 | - | $324.00 K | $324.00 K |
FAQ
- What is Spyre Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Spyre Therapeutics?
- What is Spyre Therapeutics annual SG&A year-on-year change?
- What is Spyre Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly SG&A year-on-year change?
- What is Spyre Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Spyre Therapeutics?
- What is Spyre Therapeutics TTM SG&A year-on-year change?
What is Spyre Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of SYRE is $39.95 M
What is the all time high annual SG&A for Spyre Therapeutics?
Spyre Therapeutics all-time high annual selling, general & administrative expenses is $39.95 M
What is Spyre Therapeutics annual SG&A year-on-year change?
Over the past year, SYRE annual selling, general & administrative expenses has changed by +$11.41 M (+40.01%)
What is Spyre Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of SYRE is $10.65 M
What is the all time high quarterly SG&A for Spyre Therapeutics?
Spyre Therapeutics all-time high quarterly selling, general & administrative expenses is $14.07 M
What is Spyre Therapeutics quarterly SG&A year-on-year change?
Over the past year, SYRE quarterly selling, general & administrative expenses has changed by +$2.06 M (+24.04%)
What is Spyre Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of SYRE is -$3.34 B
What is the all time high TTM SG&A for Spyre Therapeutics?
Spyre Therapeutics all-time high TTM selling, general & administrative expenses is $49.08 M
What is Spyre Therapeutics TTM SG&A year-on-year change?
Over the past year, SYRE TTM selling, general & administrative expenses has changed by -$3.37 B (-10877.40%)